InCarda Therapeutics is a biopharmaceutical company that is revolutionizing cardiovascular treatment with their innovative approach of delivering medicines through inhalation. With a focus on treating cardiovascular diseases and conditions, InCarda aims to provide effective and convenient therapies for patients. One of their key products is their Orally Inhaled Antiarrhythmic Therapy, specifically designed for patients who experience symptomatic episodes of paroxysmal atrial fibrillation (PAF).

By developing a new nebulization therapy, InCarda offers a promising solution to individuals living with this condition. The company values the feedback and experiences of actual atrial fibrillation patients, who have spoken positively about the benefits of orally inhaled flecainide. InCarda Therapeutics is committed to transforming the lives of patients by providing innovative and patient-centered treatments for cardiovascular diseases